Skip to content

Post-Traumatic Stress Disorder (PTSD)

Featured Studies

Featured studies include only those currently recruiting participants. Studies with the most recent start date appear first.

  • Procedures for Sample Acquisition and Distribution for The Human Brain Collection Core
    Study Type: Observational
    Start Date: February 20, 2018
    Location: Bethesda, Maryland
    Eligibility: Ages N/A–120, Does Not Accept Healthy Volunteers


    The Human Brain Collection Core (HBCC) collects brain and other tissues. They get these from deceased people who may or may not have had psychiatric disorders. The next of kin gives permission for researchers to get the tissues. Researchers want to collect medical details of people whose brains are donated. They also want to use the donated tissue to study brain chemistry and structure. This could lead to better treatments for mental illness.


    To create a collection of human brain tissue to learn about the causes and mechanisms of mental disorders.


    People willing to donate their deceased relative s brain tissue. The deceased person could not have had any of the following:

    Severe mental retardation

    Long-lasting seizure disorder

    Infections that affect the brain


    Brain damage

    Being on a respirator for more than 12 hours

    Major sepsis

    Serious renal or hepatic disease

    Certain dementias and degenerative diseases


    Medical Examiner s Offices will screen donors who have recently died. Some others will be screened by hospitals or funeral homes.

    Participants will be the next of kin. They will give consent for HBCC to obtain brain tissue from the deceased person. The tissue will be frozen for future research.

    Participants will have a 30-minute phone call. They will answer questions about the deceased person s medical and psychiatric conditions. They will answer questions about the person s use of medicines and drugs.

    Participants will be contacted by a social worker. They will be asked for permission to access the deceased person s medical records.

  • Identifying Neural Mechanisms of PTSD Symptom Reduction Induced by Estrogen
    Study Type: Interventional
    Start Date: November 29, 2017
    Locations: Chicago, Illinois; Philadelphia, Pennsylvania
    Eligibility: Females, Ages 18–45, Accepts Healthy Volunteers

    This study aims to first identify the optimal estradiol (E2) dose that best engages the fear extinction network among healthy women using oral contraceptives. The second objective is to then evaluate the impact of this optimal E2 dose, when administered in conjunction with 5 sessions of Prolonged Exposure therapy, on the functional activity of the fear extinction network of women with clinically significant posttraumatic stress disorder symptoms. This approach will elucidate the neural mechanisms underlying effective exposure treatment for these symptoms, and will document how estradiol could be used as adjunct to enhance the outcome of extinction-based therapies.

  • Neuroeconomics of Social Behavior Following Trauma Exposure
    Study Type: Observational
    Start Date: November 14, 2017
    Location: Belmont, Massachusetts
    Eligibility: Females, Ages 18–45, Accepts Healthy Volunteers

    This study will use a neuroeconomic paradigm with state-of-the-art imaging protocols to probe abnormal social reward processing underlying social withdrawal in symptomatic trauma-exposed women. By also gathering self-report measures of social anhedonia, performance on non-social and social reward valuation tasks, and measures of real-world social functioning including social network size, we aim to specify how alterations in social reward processing result in social withdrawal and functional impairment.

  • Suvorexant and Sleep's Benefits to Therapeutic Exposure for Posttraumatic Stress Disorder
    Study Type: Interventional
    Start Date: January 3, 2017
    Location: Washington, D.C., District of Columbia
    Eligibility: Ages 18–55, Accepts Healthy Volunteers

    The purpose of this study is to examine effects of blocking the orexin system with suvorexant after exposure-based intervention for posttraumatic stress disorder (PTSD) on sleep, PTSD symptoms, and intersession habituation.

  • Effectiveness of PTSD Treatment For Suicidal and Multi-Diagnostic Clients
    Study Type: Interventional
    Start Date: February 1, 2016
    Location: Seattle, Washington
    Eligibility: Ages 12 and Older, Does Not Accept Healthy Volunteers

    The present project has two primary aims: (1) to examine the effectiveness of a multi-component implementation strategy in improving adoption and adherence to the Dialectical Behavior Therapy Prolonged Exposure (DBT PE) protocol, and (2) to evaluate the feasibility, acceptability, and effectiveness of the DBT PE protocol in a sample of individuals receiving DBT in public mental health agencies. This study uses a hybrid type 2 effectiveness-implementation design to simultaneously test the clinical effectiveness of DBT + DBT PE and to evaluate an adaptive, multi-component implementation strategy. The effectiveness trial will use a quasi-experimental, controlled design to evaluate outcomes among DBT clients with PTSD who do versus do not receive the DBT PE protocol and outcomes will be benchmarked to those obtained in research settings.

  • Effectiveness of a Unified Transdiagnostic Treatment in Routine Care
    Study Type: Interventional
    Start Date: December 1, 2014
    Location: Boston, Massachusetts
    Eligibility: Ages 18–100, Does Not Accept Healthy Volunteers

    The purpose of this study is to examine effectiveness and implementation for the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in trauma exposed veterans.

  • Randomized Trial of Prolonged Exposure for the Treatment of Posttraumatic Stress Disorder (PTSD)
    Study Type: Interventional
    Start Date: August 1, 2013
    Location: San Juan, Puerto Rico
    Eligibility: Ages 18–64, Does Not Accept Healthy Volunteers

    This project will examine the impact of PE therapy for the treatment of PTSD with a sample of Latinos. The need to provide effective treatment to Spanish-speaking Latinos with PTSD is critical given the high prevalence of PTSD among Latinos. Furthermore, PTSD remains an under detected and under treated condition. Untreated PTSD has a substantial impact on health, functioning and quality of life. PE is one of the most empirically supported psychological interventions for PTSD. However, most studies that evidence the efficacy of PE have been conducted mainly with English-speaking Caucasian populations. This study has the potential to contribute to improvements in the well-being of Spanish-speaking Latinos with PTSD.

  • Efficacy of Single Dose IV Hydrocortisone in Post Traumatic Stress Disorder (PTSD) Prevention
    Study Type: Interventional
    Start Date: April 1, 2009
    Location: Ramat-Gan, Israel
    Eligibility: Ages 21–65, Accepts Healthy Volunteers

    This study is designed to test the hypothesis that a single Hydrocortisone intra venous injection within 6 hours post-trauma facilitates physiological recovery thereby preventing the development of Post Traumatic Stress Disorder (PTSD) in the months following the event. In the absence of such treatment (i.e., under placebo conditions), we hypothesize that a greater proportion of persons would develop PTSD (i.e., fail to recover from acute effects).

  • Development of Magnetic Resonance Imaging Techniques for Studying Mood and Anxiety Disorders
    Study Type: Observational
    Start Date: November 6, 2006
    Location: Bethesda, Maryland
    Eligibility: Ages 18–65, Accepts Healthy Volunteers

    This study is intended to help develop new MRI imaging techniques for studying mood and anxiety disorders. Researchers believe that depression and anxiety disorders may cause structural and functional changes in the brain. This study will optimize the way MRI scans are collected to look at brain structure and examine how the brain behaves while subjects perform particular tasks.

    Healthy normal subjects between 18 and 50 years of age who have never had a major psychiatric disorder and who have no first-degree relatives with mood disorders may be eligible for this study. Candidates are screened by phone with questions about their psychiatric and medical history, current emotional state and sleep pattern, and family history of psychiatric disorders. Candidates who pass the preliminary screening then undergo additional screening interviews and laboratory tests.

    Participants undergo magnetic resonance imaging (MRI) and neuropsychological testing, as follows:

    " MRI scans: Subjects are asked to participate in an MRI study on one of several scanners to measure blood flow in the brain, concentrations of certain chemicals in the brain, or magnetic properties of the brain. MRI uses a strong magnet and radio waves to obtain pictures of the brain. The subject lies still on a narrow bed with a metal coil close to the head. For this study, subjects may be asked to wear a special coil on the neck to help measure blood flow. They may be asked to watch a screen presenting images or to do a task in which they respond to pictures or sounds and may be asked to return for additional scans.

    " Neuropsychological testing: Subjects may undergo tests of cognitive performance. Often, people with mood disorders have subtle changes in performance on these tests that allow researchers to pinpoint where brain abnormalities occur. Before the tests can be used in patients, they must be validated by using healthy subjects. These tests are presented either orally, in written form, or on a computer.

  • Evaluation of Patients With Mood and Anxiety Disorders and Healthy Volunteers
    Study Type: Observational
    Start Date: September 21, 2001
    Location: Bethesda, Maryland
    Eligibility: Ages 3–99, Accepts Healthy Volunteers

    The purpose of this protocol is to allow for the careful screening of patients and healthy volunteers for participation in research protocols in the Experimental Therapeutics and Pathophysiology Lab (ETPB) at the National Institute of Mental Health (NIMH) and for the collection of natural history data. In addition the protocol will allow clinicians to gain more experience in the use of a variety of polysomnographic and high-density EEG recordings. Subjects in this protocol will undergo an evaluation which may include: a psychiatric interview; a diagnostic interview; rating scales; a medical history; a physical exam; brain magnetic resonance imaging (MRI); electroencephalography (EEG); electrocardiography (EKG), magnetoencephalography (MEG); blood, saliva and urine laboratory evaluation; and a request for medical records. Subjects may also be asked to complete questionnaires about attitudes towards research and motivation for research participation. The data collected may also be linked with data from other mood and anxiety disorder protocols (e.g., brain imaging, DNA, psychophysiology tests, treatment studies, etc) for the purposes of better understanding the diagnosis, pathophysiology, and treatment response of patients with mood disorders. Parents of minors will be interviewed. Upon conclusion of the screening process, subjects will either be offered participation in a research protocol and will sign the appropriate informed consent, or will be considered not appropriate for participation in research and will be referred back into the community. The current protocol thus serves as an entry point for individuals with mood or anxiety disorders or healthy volunteers to enter NIMH IRB approved ETPB protocols.